623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Mantle Cell Lymphoma, New Therapies


Median 3.5-Year Follow-up of Ibrutinib Treatment in Patients with Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis

Simon Rule, et al.

The authors of the study conclude:

In this pooled analysis of ibrutinib-treated R/R MCL patients with median 3.5 years of follow-up, more than a quarter of patients remained progression free and nearly half were alive at 3 years. Clinical outcomes were best for patients who achieved CR and those who were treated with ibrutinib at first relapse/progression. New onset grade ≥ 3 AEs/SAEs decreased over time.



Safety and Activity of the Highly Specific BTK Inhibitor BGB-3111 in Patients with Indolent and Aggressive Non Hodgkin’s Lymphoma

Constantine S. Tam, et al.

The authors of the study conclude:

BGB-3111 is well tolerated and active as a monotherapy in multiple NHL subtypes. Evaluation of BGB-3111 in NHL, both as monotherapy as well as in combination with other agents, is continuing in Phase 2 trials.



Rituximab Maintenance after First-Line Immunochemotherapy in Mantle Cell Lymphoma: Long-Term Follow-up of the Randomized European MCL Elderly Trial

Eva Hoster et al.

The authors of the study conclude:

After long-term follow-up we confirm the substantially prolonged PFS and OS with R-maintenance after R-CHOP induction in first-line treatment of older MCL patients who are no candidates for autologous stem cell transplantation. Despite indications for anti-lymphoma activity, induction with six cycles of R-FC was associated with severe treatment complications leading to a higher cumulative incidence of death without treatment failure and shorter survival compared with 8 cycles of R-CHOP.



Initial Treatment with Lenalidomide Plus Rituximab for Mantle Cell Lymphoma: 5-Year Follow-up and Correlative Analysis from a Multi-Center Phase II Study

Jia Ruan, et al.

The authors of the study conclude:

Lenalidomide and rituximab as initial treatment for MCL can achieve high rate of complete responses and MRD negativity with durable remissions beyond 4 years. The nature of toxicity was not significantly affected by continuous treatment, particularly in the context of close follow-up. Further evaluation of this active regimen in larger, randomized frontline trials is warranted (ClinicalTrials.gov - NCT01472562).



Efficacy and Safety of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma in the Phase 2 ACE-LY-004 Study

Michael Wang, et al.

The authors of the study conclude: 

In R/R MCL pts, treatment with single-agent acalabrutinib resulted in high ORR and CR rates, with durable and clinically meaningful responses. A favorable safety profile was also demonstrated, with a low frequency and severity of AEs and few discontinuations due to AEs. Given this favorable benefit-risk profile, acalabrutinib represents a promising treatment option for R/R MCL.



Vemurafenib in Advanced Patients with Hairy Cell Leukemia (HCL): Results of the Acsé Phase II Trial

Xavier Troussard, et al.

The authors of the study conclude:

Vemurafenib offers a feasible outpatient treatment option for relapsed/refractory patient without hematologic toxicity. These preliminary results prompt us to continue the AcSé program. Questions to be answered in the future are the optimal dosage and duration of vemurafenib, retreatment and the possibility to combine treatment with a MEK inhibitor.